About Rho GTPase-activating protein 20
Rho GTPase-activating protein 20 (ARHGAP20) is a protein
from Homo sapiens identified by UniProt accession
Q9P2F6, 1191 residues long.
MolForge cross-references it against 0 known binders and
45 disease associations.
Target properties
| Protein name | Rho GTPase-activating protein 20 |
|---|
| UniProt accession | Q9P2F6 |
|---|
| Gene | ARHGAP20 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1191 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (45)
Diseases linked to this target (Open Targets).
- FEV/FVC ratio · score 0.43
- intraocular pressure measurement · score 0.41
- neurodegenerative disease · score 0.37
- cutaneous melanoma · score 0.32
- hair color · score 0.32
- body fat percentage · score 0.24
- waist circumference · score 0.21
- self reported educational attainment · score 0.21
- heel bone mineral density · score 0.18
- prostate carcinoma · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9P2F6-F1 | alphafold | PREDICTED | 54.45 | — |
Amino-acid sequence (1191 residues)
MEAMSPQQET LGGQPGRSSS LTGVSRLAGG SCTKKKMKTL AERRRSAPSL ILDKALQKRP TTRDSPSASV DTCTFLSSLV CSNRTLLIDG RAELKRGLQR QERHLFLFND LFVVAKIKYN NNFKIKNKIK LTDMWTASCV DEVGEGNTNA MKSFVLGWPT VNFVATFSSP EQKDKWLSLL QRYINLEKEK DYPKSIPLKI FAKDIGNCAY SKTITVMNSD TANEVINMSL PMLGITGSER DYQLWVNSGK EEAPYPLIGH EYPYGIKMSH LRDSALLTPG SKDSTTPFNL QEPFLMEQLP REMQCQFILK PSRLAAAQQL SDSGHKTFKR RRSIINWAFW RGSSTHLDNL PSSPTSPMPG QLFGISLPNI CENDNLPKPV LDMLFFLNQK GPLTKGIFRQ SANVKSCREL KEKLNSGVEV HLDCESIFVI ASVLKDFLRN IPGSIFSSDL YDHWVSVMDQ GNDEEKINTV QRLLDQLPRA NVVLLRYLFG VLHNIEQHSS SNQMTAFNLA VCVAPSILWP PASSSPELEN EFTKKVSLLI QFLIENCLRI FGEEITSLFR EVSVRCDTRE NASDISCFQL NDSSYDSLEN ELNEDVDAPC SDLVKKLGQG SRSMDSVLTL SDYDLDQPEV EGLLTLSDFD LAHSKDEDVQ MKRPLESKPV NILVYTKIPL RDHARAPSAM CTPSYLSTAA ANAAKSLRRH RRCSEPSIDY LDSKLSYLRE FYQKKLRKSS CDAILSQKDE DYLKQNQPLQ EEGKTCFKQS LVTGTDVSKK NATTQNTKKK SLSGSEGNHV KLFPKSKPVA ISVASYSPMS SQDHSKNQPF DVNTSGYSPP HTADALKGPR THRRCSEPNI EDQNRKLTYL RGIYSKKQHK TSCEAGLLHG EEDYLKRHKS LQMEGQKLIN QSLVMGIEVG KSSATNQNTE KVLPPRLNLC PRTSYSSLSS PGTSPSGSSV SSQDSAFSQI SEHSVFTPTE TSSPIDCTFQ AQRKREDLSP DFSNASHVSG MPGPSSGQAC SRPAYTKKDT MEWHSQMHSV TLHPSTWLRN GVASLKNWSL KKKAKAARPE EEKIASPKGP LEPPPHASGV PEANSLQEEQ KDLPLRAAEG LSPVQSAQRC SSSPFQDSER HCSSPFSLVE SRLKLCMKSH EEIEPGSQSS SGSLPWERAS ASSWTLEDAT SPDSGPTVVC DIEDRYLTKD I
Explore Rho GTPase-activating protein 20 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets